In summary, GSR deficiency exacerbates and promotes pulmonary fibrosis by inhibiting GSH levels and increasing the accumulation of ROS, thereby activating the TGF-β/Smad2 signaling pathway, suggesting GSR is a potential therapeutic target for IPF. Here, SMAD2 is linked to idiopathic pulmonary fibrosis.